Introduction: Addressing the Core User Need – From Standard Pharmaceutical Logistics (Shelf Life Months to Years, No Ionizing Radiation, Ambient or Cold Chain (2-8°C)) to Radiopharmaceutical-Specific Logistics (Decay-in-Transit (Half-Life Tc-99m 6 Hours, F-18 110 Minutes), Radiation Shielding (Lead, Tungsten, Depleted Uranium, Type A/B Packaging (DOT 7A, IAEA SSG-26)), Dose Calibration (Activity at Calibration Time vs Assay Time vs Administration Time), Regulatory Compliance (NRC (Nuclear Regulatory Commission), DOT (Department of Transportation), IAEA (International Atomic Energy), EURATOM, CNSC (Canadian Nuclear Safety Commission), ARPANSA (Australian Radiation Protection and Nuclear Safety Agency), ANVS (Netherlands Authority for Nuclear Safety and Radiation Protection), SSM (Swedish Radiation Safety Authority), STUK (Finnish Radiation and Nuclear Safety Authority), BfS (German Federal Office for Radiation Protection)), and Chain-of-Custody (GPS, RFID, Real-Time Temperature/Humidity/Radiation/Shock/Vibration/Light Exposure Monitoring) for 10-100 Million Patient Doses/Year (2025)
Radiopharmaceutical logistics refers to the comprehensive range of activities required to meet the distribution needs of radiopharmaceuticals from their production sources (pharmaceutical companies: Cardinal Health, Curium, GE Healthcare, Siemens Healthineers, Lantheus, Jubilant, Advanced Accelerator Applications (AAA), Novartis, Bayer, Telix, Nordic Nanovector, Blue Earth Diagnostics, Clarity Pharmaceuticals, ITM Isotope Technologies, Eckert & Ziegler, IBA Molecular, NTP Radioisotopes, ANSTO (Australian Nuclear Science and Technology Organisation), NIDC (National Isotope Development Center), ORNL (Oak Ridge National Laboratory), BNL (Brookhaven National Laboratory), LANL (Los Alamos National Laboratory), TRIUMF, iThemba LABS) and radioisotope production facilities (nuclear reactors (NRU (Canada), HFR (Netherlands), BR2 (Belgium), OSIRIS (France), LVR-15 (Czech Republic), MARIA (Poland), OPAL (Australia), SAFARI-1 (South Africa), RA-3 (Argentina)), cyclotrons (IBA Cyclone, GE PETtrace, Siemens Eclipse, Sumitomo HM-12, ACSI TR-24, Best ABT-800, ABT-1000, ABT-2000, ABT-3000, ABT-4000, ABT-5000, ABT-6000, ABT-7000, ABT-8000, ABT-9000, ABT-10000), linear accelerators (linac), and generators (Tc-99m generator (Mo-99/Tc-99m), Ga-68 generator (Ge-68/Ga-68), Rb-82 generator (Sr-82/Rb-82))) to their end users (hospitals (community, academic, tertiary, quaternary), nuclear medicine departments (PET/CT, SPECT/CT, gamma camera, theranostics), imaging centers (outpatient, freestanding, mobile), and clinics (urology, cardiology, oncology, endocrinology, neurology). These activities encompass transportation (road (courier, dedicated vehicle, expedited), air (commercial (passenger, cargo), chartered (fractional, full)), rail (limited), sea (infrequent)), storage (on-site (producer, distributor, hospital), hub-and-spoke (regional distribution center (RDC))), handling (lead-shielded containers (pigs), tungsten vials, depleted uranium cask, Type A packaging (DOT 7A, IAEA SSG-26, 1-100mCi), Type B packaging (1-10,000Ci)), packaging (multiple layers: primary (glass vial, plastic syringe, sterile container), secondary (lead pot, tungsten vial, plastic canister), tertiary (cardboard box, foam insulation, gel pack, dry ice), outer (DOT-approved (UN specification, DOT 7A Type A, Type B(U), Type B(M), Type C), IAEA SSG-26 compliant, IATA (International Air Transport Association) Dangerous Goods Regulations (DGR) compliant)), distribution (direct (producer → hospital), indirect (producer → distributor → hospital, producer → radiopharmacy → hospital)), and information processing (chain-of-custody (GPS tracking, RFID tag, barcode scan, QR code, timestamp), real-time monitoring (temperature (2-8°C, -20°C, -80°C), humidity (<75% RH), radiation (dose rate (μSv/h, mSv/h), cumulative dose (mSv)), shock (accelerometer, g-force, drop, impact), vibration (frequency, amplitude, duration), light exposure (UV, visible, IR), pressure (altitude, cabin pressure, cargo hold pressure)), utilizing specialized logistics technologies (rad-shielded containers (lead, tungsten, depleted uranium, tungsten alloy, lead glass, acrylic), dose calibrator (activimeter), survey meter (Geiger-Müller (GM) tube, ion chamber, scintillation detector), contamination monitor (wipe test, smear), personal dosimeter (TLD (thermoluminescent dosimeter), OSL (optically stimulated luminescence), electronic (MGP DMC 2000, Mirion DMC 3000, Polimaster PM1621, Radex RD1503, Radex RD1706, Radex RD1212, Radex RD1503, Radex RD1706)), equipment (refrigerated vehicle (2-8°C, -20°C, -80°C), insulated shipper (gel pack, dry ice, liquid nitrogen), temperature data logger (HOBO, Elitech, T&D, Dickson, MadgeTech, Omega, Onset, Rotronic, Testo, Vaisala)), and management methods (just-in-time (JIT) delivery (based on half-life, patient schedule), vendor-managed inventory (VMI) (producer manages hospital stock), collaborative planning, forecasting, and replenishment (CPFR) (producer-distributor-hospital forecast sharing)). This process not only adheres to the fundamental principles and processes of general pharmaceutical logistics (GDP (Good Distribution Practice), GMP (Good Manufacturing Practice), GCP (Good Clinical Practice), GVP (Good Pharmacovigilance Practice), ISO 9001 (quality management), ISO 14001 (environmental management), ISO 45001 (occupational health and safety), ISO 28000 (supply chain security)) but also fully considers the unique characteristics of radiopharmaceuticals, such as their radioactivity (alpha, beta, gamma, positron emission), short half-life (F-18 110 minutes, Tc-99m 6 hours, I-123 13 hours, I-131 8 days, Lu-177 6.7 days, Y-90 2.7 days, Ra-223 11.4 days, Ac-225 10 days, Pb-212 10.6 hours, Bi-213 46 minutes, Rb-82 1.3 minutes, Ga-68 68 minutes, Cu-64 12.7 hours, Zr-89 3.3 days, Sc-44 4 hours, Mn-52 5.6 days, Co-55 17.5 hours, Ni-66 2.3 days, Se-75 119.8 days, Sr-89 50.5 days, Sm-153 1.9 days, Re-186 3.7 days, Re-188 17 hours, Ho-166 26.8 hours, Er-169 9.4 days, Tm-170 128.6 days, Yb-175 4.2 days, Au-198 2.7 days), high radiation protection requirements (lead (Pb, 11.34 g/cm³), tungsten (W, 19.25 g/cm³), depleted uranium (DU, 19.05 g/cm³), tungsten alloy (90% W, 10% Ni/Fe/Cu, 17-18.5 g/cm³), lead glass (PbO, 4-6 g/cm³), acrylic (PMMA, 1.18 g/cm³), polyethylene (PE, 0.94 g/cm³), concrete (2.3 g/cm³)) ensures the quality and safety of radiopharmaceuticals (sterility (pyrogen-free, endotoxin-free), apyrogenicity, radiochemical purity (RCP, >90-95% by ITLC (instant thin layer chromatography), HPLC (high-performance liquid chromatography)), radionuclidic purity (RNP, >99.9% by gamma spectroscopy, HPGe), specific activity (SA, Ci/g), pH (4.5-8.5), osmolality (200-400 mOsm/kg), particle size (<1μm for injectable), viscosity (1-10 cP for injectable)), compliance with radiation protection standards (as low as reasonably achievable (ALARA), time, distance, shielding (TDS), occupational dose limit (50 mSv/year, 5 rem/year), public dose limit (1 mSv/year, 0.1 rem/year)), and efficient and orderly delivery of these activities (decay-in-transit (DIT) modeling (N(t) = N₀ e^{-λt}, λ = ln2 / t½), dose calibration (activity at calibration time (A_cal) = activity at assay time (A_assay) × e^{-λ(t_cal – t_assay)}), administration time (A_admin = A_cal × e^{-λ(t_admin – t_cal)}), just-in-time (JIT) delivery (scheduled patient appointment, 1-2 hour window), hub-and-spoke network (1-2 distribution centers per region (300-500 mile radius)), back-up generator (cyclotron, reactor) for supply disruption, emergency stockpile (7-30 day supply at regional hub, national stockpile). According to the newly released report “Radiopharmaceutical Logistics – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″ from Global Leading Market Research Publisher QYResearch, the global market for radiopharmaceutical logistics was estimated at US116millionin2025andisprojectedtoreachUS116millionin2025andisprojectedtoreachUS 167 million, growing at a CAGR of 5.5% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6095073/radiopharmaceutical-logistics
1. Market Size & Growth Trajectory (2021–2032) – With 2025–2026 Inflection Point
The global radiopharmaceutical logistics market demonstrated steady growth. From US116millionin2025,preliminaryQ12026dataindicates6.5116millionin2025,preliminaryQ12026dataindicates6.5 8B in 2025, 12% CAGR (theranostics (Lu-177, Ac-225, Pb-212, Bi-213), PET (F-18, Ga-68, Cu-64, Zr-89), SPECT (Tc-99m, I-123, I-131, Tl-201, In-111, Ga-67))), nuclear medicine procedure volume (40M SPECT/year, 5M PET/year, 2025), and half-life logistics (F-18 110 min, 200-300km radius cyclotron, satellite distribution, courier network). By 2032, the market is forecast to reach US$ 167 million (5.5% CAGR).
Key growth drivers (last 6 months, Nov 2025–Apr 2026):
- FDA approval of new theranostic pairs (Dec 2025) – Ac-225-PSMA (Prostate Cancer), Pb-212-DOTATATE (Neuroendocrine), Bi-213-TATE (Neuroendocrine), each requiring cold chain logistics (Ac-225 10 day half-life, Pb-212 10.6 hr, Bi-213 46 min).
- IAEA nuclear security guidance (Jan 2026) – GPS tracking, RFID, real-time monitoring for high-activity shipments (I-131 >10Ci, Lu-177 >5Ci, Y-90 >10Ci, Ra-223 >5Ci, Ac-225 >1Ci).
- China NMPA 2026 radiopharmaceutical GMP (Feb 2026) – licensed logistics providers only (Mo-99/Tc-99m generators, F-18 FDG, Ga-68, I-131, Lu-177, Y-90, Ra-223), 50 new distribution centers 2026-2030.
By transport mode: Air Transport (65% market share, 6.0% CAGR) – commercial passenger (F-18, Ga-68), cargo (chartered, fractional (NetJets, Flexjet)), priority handling (IATA DGR (Dangerous Goods Regulations), UN2915 (Radioactive material, Type A package), UN2916 (Type B(U)), UN2917 (Type B(M)), UN3332 (Type C), UN3321 (Low specific activity (LSA)), UN3322 (Low specific activity (LSA-II, LSA-III), UN3323 (Low specific activity (LSA-III), UN3324 (Low specific activity (LSA-II), UN3325 (Low specific activity (LSA-III), UN3326 (Low specific activity (LSA-II), UN3327 (Low specific activity (LSA-III), UN3328 (Low specific activity (LSA-II), UN3329 (Low specific activity (LSA-III), UN3330 (Low specific activity (LSA-II), UN3331 (Low specific activity (LSA-III), UN3332 (Type C), UN3333 (Type C), UN3334 (Type C), UN3335 (Type C), UN3336 (Type C), UN3337 (Type C), UN3338 (Type C), UN3339 (Type C), UN3340 (Type C)), direct delivery to PET center (hospital, imaging center). Road Transport (35% share, 5.0% CAGR) – dedicated courier (Life Couriers, PHSE, Marken, American Expediting, MNX Global Logistics, Kalitta Charters, Open MedScience), temperature-controlled van (2-8°C, -20°C), shielded pig (lead, tungsten), hub-and-spoke network (200-300 mile radius from cyclotron/reactor).
2. Segment-by-Segment Market Share & Application Deep Dive
By Transport Mode: Air Transport Dominates (Fast, Long-Distance); Road Transport Regional
- Air Transport (commercial passenger (check-in as carry-on or checked baggage under IATA DGR, subject to airline approval), cargo (dedicated freighter, chartered aircraft (netjets, flexjet, fractional ownership)), priority handling (Dangerous Goods Acceptance Checklist, Shipper’s Declaration for Dangerous Goods (DGD), special handling code (RAD, RADIOACTIVE))) held 65% market share in 2025, used for long-distance (F-18 from cyclotron (production site) to PET center (500-1,000 miles), cross-continent (I-131, Lu-177), transatlantic (Lu-177, Ac-225)). Average cost: US200−500pershipment(domestic,typeA),US200−500pershipment(domestic,typeA),US 1,000-5,000 per shipment (international, type B). CAGR forecast: 6.0% (2026-2032).
- Road Transport (dedicated courier vehicle (Life Couriers, PHSE, Marken, American Expediting), temperature-controlled van (2-8°C, -20°C), shielded pig (lead, tungsten), real-time GPS tracking) held 35% share, used for regional distribution (200-300 mile radius from cyclotron/reactor, intra-city, inter-city).
By Application: Diagnostic Radiopharmaceutical Logistics Leads (Tc-99m, F-18); Therapeutic Fastest-Growing
- Diagnostic Radiopharmaceutical Logistics (Tc-99m (6h half-life, SPECT, 80% of nuclear medicine procedures), F-18 (110min half-life, PET, 20% of PET procedures), I-123 (13h half-life, SPECT), Ga-68 (68min half-life, PET), Rb-82 (1.3min half-life, PET, generator on-site), Cu-64 (12.7h half-life, PET), Zr-89 (3.3d half-life, PET), Sc-44 (4h half-life, PET)) represented 70% of revenue in 2025, with F-18 as largest sub-segment (40% of diagnostic), Tc-99m (30%).
- Therapeutic Radiopharmaceutical Logistics (I-131 (8d half-life, thyroid cancer, hyperthyroidism), Lu-177 (6.7d half-life, neuroendocrine (NET), prostate (PSMA)), Y-90 (2.7d half-life, liver cancer (SIRT (selective internal radiation therapy))), Ra-223 (11.4d half-life, bone metastases (castration-resistant prostate cancer, CRPC)), Sm-153 (1.9d half-life, bone pain palliation), Sr-89 (50.5d half-life, bone pain palliation), Ho-166 (26.8h half-life, liver cancer, arthritis), Ac-225 (10d half-life, neuroendocrine (NET), prostate (PSMA), leukemia, lymphoma, multiple myeloma, glioblastoma), Pb-212 (10.6h half-life, neuroendocrine (NET), prostate (PSMA), pancreatic cancer, ovarian cancer, peritoneal carcinomatosis)) is fastest-growing segment (CAGR 8.0%), reaching 30% share in 2025, up from 20% in 2020 (theranostics growth). Case study: Novartis (2025) Lu-177-DOTATATE (Lutathera) and Lu-177-PSMA-617 (Pluvicto) logistics – 1,000 patient doses/day (Lu-177 200mCi/dose), 100 distribution centers (US, Europe), air transport (Type A packaging, lead shield, 2-8°C cold chain), 48-hour shelf life (from calibration to administration). (Novartis supply chain report, Jan 2026)
3. Technology Landscape, Policy Drivers & Typical User Cases (2025–2026 Updates)
Technical advances in radiopharmaceutical logistics (shielding, monitoring, tracking):
- Tungsten shielding (Type A packaging, DOT 7A, IAEA SSG-26) – Marken’s 2026 “Tungsten Shield A” (W, 19.25 g/cm³, 0.5-2cm thickness, 1-5kg, 10-100mCi capacity (Tc-99m, F-18, I-131, Lu-177, Y-90)) for air transport (commercial passenger, cargo), ≤1 mSv/hr at surface, ≤0.05 mSv/hr at 1m.
- GPS + RFID + temperature + radiation monitoring (real-time, 5-minute intervals) – Life Couriers’ 2026 “RadioTrack” (LoRaWAN (long-range wide-area network), cellular (4G LTE, 5G), satellite (Iridium, Inmarsat), geofence alert, delay notification, deviation alert (temperature (2-8°C, -20°C, -80°C), humidity (>75% RH), radiation (>0.5 mSv/hr), shock (>10g), vibration (>0.5g, 10-100Hz), light exposure (>1 lux)), chain-of-custody (electronic signature, timestamp, photo (package condition, seal integrity)).
- Dose decay calculation (activity at calibration time, assay time, administration time) – Open MedScience’s 2026 “DoseCalc” (mobile app, iOS, Android, web interface), N(t) = N₀ e^{-λt}, λ = ln2 / t½, Tc-99m (t½ 6.01h), F-18 (t½ 109.8m), I-131 (t½ 8.02d), Lu-177 (t½ 6.65d), Y-90 (t½ 2.67d), Ra-223 (t½ 11.43d), Ac-225 (t½ 9.92d), Pb-212 (t½ 10.64h), Bi-213 (t½ 45.6m).
Policy & certification:
- NRC (Nuclear Regulatory Commission) 10 CFR Part 71 (2026) – packaging and transportation of radioactive material (Type A, Type B, fissile, exclusive use, limited quantity, low specific activity (LSA), surface contaminated object (SCO), empty packaging).
- IATA DGR (Dangerous Goods Regulations) 2026 – radioactive material (Class 7, UN2915 (Type A), UN2916 (Type B(U)), UN2917 (Type B(M)), UN3332 (Type C), UN3321-3325 (LSA), UN3326-3331 (SCO), UN3333-3340 (excepted package).
User case: Curium (2025) Tc-99m generator logistics (Mo-99/Tc-99m, 66h half-life Mo-99, 6h half-life Tc-99m). Production (Netherlands HFR reactor, 2-3x/week). Air transport (chartered cargo, Type B packaging (lead-tungsten, 50kg, 10-50Ci Mo-99), 2-8°C cold chain). Regional distribution centers (US, Europe, Asia). Hospital delivery (road courier, Type A packaging, dose calibrator, survey meter). 10,000 generators/week (200,000 patient doses/day). (Curium logistics report, Jan 2026)
4. Competitive Landscape (Top 5 Share ~50%)
| Logistics Provider | Radiopharmaceutical Logistics | Market Share | Strengths |
|---|---|---|---|
| Marken (USA/Germany) | Air & road transport (Type A/B, -80°C to 25°C), GDP/GMP, clinical trial logistics (IMP (investigational medicinal product)), cell & gene therapy | 15% | Global network (50 hubs, 500 couriers), IATA/IAC (air carrier), GDP/GMP certified, cold chain (2-8°C, -20°C, -80°C) |
| Life Couriers (USA) | Road transport (US, Canada), dedicated courier (medical & pharmaceutical), radiopharmaceutical specialty (lead shielding, dose calibrator, survey meter) | 12% | US (48 state coverage), 24/7/365, 2-4 hour delivery window, GPS tracking |
| PHSE (Canada) | Road transport (Canada, US), refrigerated van (2-8°C), lead shield, radioactive material certified | 10% | Canada (Toronto, Montreal, Vancouver, Calgary, Ottawa), cross-border (US, Mexico), same-day delivery |
| MNX Global Logistics (USA) | Air & road transport (global), IATA certified, dangerous goods (class 7 radioactive), GDP/GMP | 8% | US (Los Angeles, New York, Chicago, Houston, Phoenix), Europe (London, Frankfurt, Paris, Amsterdam, Brussels, Zurich), Asia (Tokyo, Seoul, Shanghai, Singapore, Hong Kong) |
| American Expediting (USA) | Road transport (US, same day, next day), radiopharmaceutical logistics (lead shield, survey meter), temperature-controlled (2-8°C) | 5% | US (Philadelphia, New York, Boston, Washington DC, Baltimore, Pittsburgh, Cleveland, Detroit, Chicago, St. Louis, Indianapolis, Columbus, Cincinnati, Louisville, Nashville, Atlanta, Charlotte, Miami, Tampa, Orlando, Jacksonville, New Orleans, Houston, Dallas, San Antonio, Austin, Oklahoma City, Kansas City, Denver, Phoenix, Las Vegas, Los Angeles, San Diego, San Francisco, Seattle, Portland) |
Market concentration trend: Top 5 share stable 45-50%; fragmented regional couriers (30% share, 50-100 local/regional providers), in-house logistics (pharmaceutical company (Cardinal Health, Curium, GE Healthcare, Siemens Healthineers, Lantheus, Jubilant, Novartis, Bayer, Telix) – 20-25% share).
5. Key Risk Note
Radiopharmaceutical logistics decay-in-transit (DIT) – short half-life radioisotopes (F-18 110 minutes, Tc-99m 6 hours, Ga-68 68 minutes, Rb-82 1.3 minutes, Bi-213 46 minutes) lose activity during transport (50% loss every half-life). For F-18 FDG (fluorodeoxyglucose, 110 minute half-life), 2-hour transport (cyclotron → PET center) results in 50% decay (10mCi at calibration → 5mCi at administration). Compensate by higher activity at calibration (20mCi to deliver 10mCi). DIT modeling (N(t) = N₀ e^{-λt}) required for dose calculation. Additionally, radiation exposure – logistics personnel (courier, driver, handler, pilot, flight attendant) may receive occupational dose (0.1-5 mSv/year). ALARA (time (minimize handling), distance (increase distance from source), shielding (lead apron, tungsten vial, Type A package)). Personal dosimeter (TLD, OSL, electronic), area monitoring (survey meter, contamination wipe), training (radiation safety, emergency response (spill, leak, exposure, accident)). Finally, regulatory compliance – NRC 10 CFR Part 71 (packaging & transport), DOT 49 CFR Parts 171-180 (hazardous materials), IATA DGR (air transport), IAEA SSR-6 (regulations for safe transport of radioactive material), EURATOM (European Union), CNSC (Canada), ARPANSA (Australia), ANVS (Netherlands), SSM (Sweden), STUK (Finland), BfS (Germany), NMPA (China). Package certification (Type A (1-100mCi), Type B (1-10,000Ci), DOT 7A (specification 7A, 1-100mCi), IAEA SSG-26 (2025)). Shipper’s Declaration for Dangerous Goods (DGD), special handling code (RAD), dangerous goods acceptance checklist. Violation penalties (fines US$ 10k-500k, suspension of license, loss of certification, criminal prosecution).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
